Alvotech (ALVO) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.03
- Estimate
- -$0.06
- Surprise
- +42.0%
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Alvotech (ALVO) reported a narrower loss than forecast — adjusted EPS of -$0.03 against the -$0.06 estimate (a 42.0% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates ALVO Sell at 5.2/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +42.0% surprise compares with a +68.1% four-quarter average.
What argues against it
- Quality below floor (4.0 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.92
- Price target
- $6.53
- Stop
- $4.58
- Upside to target
- +32.7%
- Reward-to-risk
- 3.5:1
Model outputs from TrendMatrix’s engine as of 2026-11-12 — shown for context, not personalized investment advice.
ALVO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.76B
- P/E (fwd)
- 21.1
- 52-week range
- $2.94–$6.53
- Off 52-week high
- 24.7%
- RSI (14)
- 53
- Volume vs avg
- 0.98×
- Score today
- 5.2/10